Citations (64)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
David Qualls & Anita Kumar. (2023) Personalized approaches for treatment-naïve mantle cell lymphoma. Expert Review of Hematology 16:2, pages 95-107.
Read now
Read now
Neerav Monga, Jamie Garside, Joan Quigley, Moira Hudson, Peter O’Donovan, John O’Rourke, Christoph Tapprich, Lori Parisi, Matthew S. Davids & Constantine Tam. (2020) Systematic literature review of the global burden of illness of mantle cell lymphoma. Current Medical Research and Opinion 36:5, pages 843-852.
Read now
Read now
Martin Dreyling, Igor Aurer, Sergio Cortelazzo, Olivier Hermine, Georg Hess, Mats Jerkeman, Steven Le Gouill, Vincent Ribrag, Marek Trněný, Carlo Visco, Jan Walewski, Francesco Zaja & Pier Luigi Zinzani. (2018) Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations. Leukemia & Lymphoma 59:8, pages 1814-1828.
Read now
Read now
Tadeusz Robak. (2016) Novel therapies under investigation for mantle cell lymphoma. Expert Opinion on Investigational Drugs 25:4, pages 375-380.
Read now
Read now
Piotr Smolewski, Magdalena Witkowska & Tadeusz Robak. (2015) Treatment options for mantle cell lymphoma. Expert Opinion on Pharmacotherapy 16:16, pages 2497-2507.
Read now
Read now
Vicki A. Morrison, Sin-Ho Jung, Jeffrey Johnson, Ann LaCasce, Kristie A. Blum, Nancy L. Bartlett, Brandelyn N. Pitcher & Bruce D. Cheson. (2015) Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501). Leukemia & Lymphoma 56:4, pages 958-964.
Read now
Read now
David Salek, Pavla Vesela, Ludmila Boudova, Andrea Janikova, Pavel Klener, Samuel Vokurka, Milada Jankovska, Robert Pytlik, David Belada, Jan Pirnos, Mojmir Moulis, Roman Kodet, Michal Michal, Eva Janousova, Jan Muzik, Jiri Mayer & Marek Trněný. (2014) Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Database. Leukemia & Lymphoma 55:4, pages 802-810.
Read now
Read now
Giulia Benevolo, Annalisa Chiappella & Umberto Vitolo. (2013) The risk of CNS involvement in aggressive lymphomas in the rituximab era. Expert Review of Hematology 6:6, pages 643-652.
Read now
Read now
Peter Martin & Bijal Shah. (2013) Limited-stage mantle cell lymphoma: not so different from advanced-stage. Leukemia & Lymphoma 54:2, pages 217-218.
Read now
Read now
Articles from other publishers (55)
Allison M. Bock, Jennifer J. Gile, Melissa C. Larson, Kittika Poonsombudlert, Reema K. Tawfiq, Seth Maliske, Matthew J. Maurer, Brian F. Kabat, Jonas Paludo, David J. Inwards, Sabarish Ayyappan, Brian K. Link, Stephen M. Ansell, Thomas M. Habermann, Thomas E. Witzig, Grzegorz S. Nowakowski, James R. Cerhan, Umar Farooq & Yucai Wang. (2023) Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort study. Blood Cancer Journal 13:1.
Crossref
Crossref
Dilan Patel & Brad Kahl. (2023) SOHO State of the Art Updates and Next Questions: Tailoring Upfront Therapy in Mantle Cell Lymphoma. Clinical Lymphoma Myeloma and Leukemia 23:9, pages 633-641.
Crossref
Crossref
Marina Knudsen Kirkegaard. (2022) Ocular adnexal lymphoma: Subtype‐specific clinical and genetic features. Acta Ophthalmologica 100:S270, pages 3-37.
Crossref
Crossref
Francis R. LeBlanc, Zainul S. Hasanali, August Stuart, Sara Shimko, Kamal Sharma, Violetta V. Leshchenko, Samir Parekh, Haiqing Fu, Ya Zhang, Melvenia M. Martin, Mark Kester, Todd Fox, Jiangang Liao, Thomas P. Loughran, Juanita Evans, Jeffrey J. Pu, Stephen E. Spurgeon, Mirit I. Aladjem & Elliot M. Epner. (2022) Combined epigenetic and immunotherapy for blastic and classical mantle cell lymphoma. Oncotarget 13:1, pages 986-1002.
Crossref
Crossref
Chenglan Lv, Jing Wang, Min Zhou, Jing-Yan Xu, Bing Chen & Yuan Wan. (2022) Primary central nervous system lymphoma in the United States, 1975–2017. Therapeutic Advances in Hematology 13, pages 204062072110661.
Crossref
Crossref
Radhika Takiar & Tycel Phillips. (2021) Non-chemotherapy Options for Newly Diagnosed Mantle Cell Lymphoma. Current Treatment Options in Oncology 22:11.
Crossref
Crossref
Dominik Dabrowski, Roberto F. Silva, Michael Constantinescu, Rodney E. Shackelford, Nestor Dela Cruz & Eric X. Wei. (2020) Synchronous Occurrence of Splenic Pleomorphic Mantle Cell Lymphoma and Esophageal Adenocarcinoma with Overexpression of BCL1 Protein. Case Reports in Oncological Medicine 2020, pages 1-7.
Crossref
Crossref
Hongyu Wu, Jianwei Wang, Xuanye Zhang, Hang Yang, Yu Wang, Peng Sun, Qingqing Cai, Yi Xia & Panpan Liu. (2020) Survival Trends in Patients Under Age 65 Years With Mantle Cell Lymphoma, 1995–2016: A SEER-Based Analysis. Frontiers in Oncology 10.
Crossref
Crossref
Jason T. Romancik & Jonathon B. Cohen. (2020) Is Limited-Stage Mantle Cell Lymphoma Curable and How Is It Best Managed?. Hematology/Oncology Clinics of North America 34:5, pages 849-859.
Crossref
Crossref
Sergio Cortelazzo, Maurilio Ponzoni, Andrés J.M. Ferreri & Martin Dreyling. (2020) Mantle cell lymphoma. Critical Reviews in Oncology/Hematology 153, pages 103038.
Crossref
Crossref
Mohamed Gomaa Kamel, Amr Ehab El-Qushayri, Ahmed Kamal Sayed & Nguyen Tien Huy. (2020) Using the primary site as a prognostic tool for nodal mantle cell lymphoma: a SEER-based study. Journal of Comparative Effectiveness Research 9:12, pages 861-876.
Crossref
Crossref
Sharon Ben Barouch, John Kuruvilla, Richard W. Tsang, Eva Yashphe & Nadav Sarid. (2020) Radiotherapy in mantle cell lymphoma: A literature review. Hematological Oncology 38:3, pages 223-228.
Crossref
Crossref
Sergio Augusto Buzian Brasil, Carolina Colaço, Tomas Barrese, Roberto P. Paes, Cristina Bortolheiro & Rodolfo Delfini Cançado. (2020) Non-indolent mantle cell lymphoma at a single public hospital in Brazil: real world first-line treatment cohort study data. Hematology, Transfusion and Cell Therapy 42:1, pages 93-97.
Crossref
Crossref
Ziduo Li, Edward Abadir, Kenneth Lee, Candice Clarke, Christian E Bryant, Wendy Cooper, Geoffrey Pietersz, James Favaloro, Pablo A Silveira, Derek NJ Hart, Xinsheng Ju & Georgina J Clark. (2020) Targeting CD83 in mantle cell lymphoma with anti‐human CD83 antibody. Clinical & Translational Immunology 9:7.
Crossref
Crossref
Stephen E. Spurgeon, Kamal Sharma, David F. Claxton, Christopher Ehmann, Jeffrey Pu, Sara Shimko, August Stewart, Nan Subbiah, Gundula Palmbach, Francis LeBlanc, Emile Latour, YiYi Chen, Motomi Mori, Zainul Hasanali & Elliot M. Epner. (2019) Phase 1–2 study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed B‐cell non‐Hodgkin lymphoma and previously untreated mantle cell lymphoma. British Journal of Haematology 186:6, pages 845-854.
Crossref
Crossref
James N. Gerson & Stefan K. Barta. (2019) Mantle Cell Lymphoma: Which Patients Should We Transplant?. Current Hematologic Malignancy Reports 14:4, pages 239-246.
Crossref
Crossref
Isabelle Doignon, Olivier Fayol & Olivier Dellis. (2019) Improvement of the rituximab–induced cell death by potentiation of the store-operated calcium entry in mantle cell lymphoma cell lines. Oncotarget 10:43, pages 4466-4478.
Crossref
Crossref
James N. Gerson, Elizabeth Handorf, Diego Villa, Alina S. Gerrie, Parv Chapani, Shaoying Li, L. Jeffrey Medeiros, Michael I. Wang, Jonathon B. Cohen, Oscar Calzada, Michael C. Churnetski, Brian T. Hill, Yazeed Sawalha, Francisco J. Hernandez-Ilizaliturri, Shalin Kothari, Julie M. Vose, Martin A. Bast, Timothy S. Fenske, Swapna Narayana Rao Gari, Kami J. Maddocks, David Bond, Veronika Bachanova, Bhaskar Kolla, Julio Chavez, Bijal Shah, Frederick Lansigan, Timothy F. Burns, Alexandra M. Donovan, Nina Wagner-Johnston, Marcus Messmer, Amitkumar Mehta, Jennifer K. Anderson, Nishitha Reddy, Alexandra E. Kovach, Daniel J. Landsburg, Martha Glenn, David J. Inwards, Reem Karmali, Jason B. Kaplan, Paolo F. Caimi, Saurabh Rajguru, Andrew Evens, Andreas Klein, Elvira Umyarova, Bhargavi Pulluri, Jennifer E. Amengual, Jennifer K. Lue, Catherine Diefenbach, Richard I. Fisher & Stefan K. Barta. (2019) Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era. Journal of Clinical Oncology 37:6, pages 471-480.
Crossref
Crossref
Shuangshuang Fu, Michael Wang, Ruosha Li, David R. Lairson, Bo Zhao & Xianglin L. Du. (2019) Increase in survival for patients with mantle cell lymphoma in the era of novel agents in 1995–2013: Findings from Texas and national SEER areas. Cancer Epidemiology 58, pages 89-97.
Crossref
Crossref
Marian Grace Ana-Magadia, Yasuhiro Takahashi, Ma. Regina Paula Valencia & Hirohiko Kakizaki. (2019) Mantle Cell Lymphoma of the Lacrimal Gland. Journal of Craniofacial Surgery 30:1, pages 158-160.
Crossref
Crossref
Jing-Song He, Xi Chen, Guo-Qing Wei, Jie Sun, Wei-Yan Zheng, Ji-Min Shi, Wen-Jun Wu, Yi Zhao, Gao-Feng Zheng, He Huang & Zhen Cai. (2019) Simplified MIPI-B prognostic stratification method can predict the outcome well—retrospective analysis of clinical characteristics and management of newly-diagnosed mantle cell lymphoma patients from China. Medicine 98:1, pages e13741.
Crossref
Crossref
Xinxin Zhang, Kathleen B. Gordon, Renzo A. Zaldivar & Lamise Z. Rajjoub. (2018) Mantle cell lymphoma: conjunctival mass in a female patient. Canadian Journal of Ophthalmology 53:3, pages e109-e111.
Crossref
Crossref
Christopher M. Knapp, Jia He, John Lister & Kathryn A. Whitehead. (2018) Lipid nanoparticle siRNA cocktails for the treatment of mantle cell lymphoma. Bioengineering & Translational Medicine 3:2, pages 138-147.
Crossref
Crossref
Alexandra Smith, Eve Roman, Simon Appleton, Debra Howell, Rod Johnson, Cathy Burton & Russell Patmore. (2018)
Impact of novel therapies for mantle cell lymphoma in the real world setting: a report from the
UK
's Haematological Malignancy Research Network (
HMRN
)
. British Journal of Haematology 181:2, pages 215-228.
Crossref
Crossref
K.D. Kaplanov, N.P. Volkov, T.Yu. Klitochenko, A.L. Shipaeva, I.V. Matveeva, M.N. Shirokova, A.C. Proskurina, N.A. Red'kina & E.G. Gemdzhian. (2018) First-Line Treatment of Mantle-Cell Lymphoma: Analysis of Effectiveness and Cost-Effectiveness. Clinical oncohematology 11:2, pages 150-159.
Crossref
Crossref
Vijaya Raj Bhatt, Roberto Ferro Valdes & Julie M. Vose. 2018. Hematology. Hematology
1298
1308.e2
.
B.S. Dabaja, A.D. Zelenetz, A.K. Ng, R.W. Tsang, S. Qi, P.K. Allen, D. Hodgson, U. Ricardi, R.T. Hoppe, R. Advani, P.M. Mauch, L.S. Constine, L. Specht, Y. Li, S.A. Terezakis, A. Wirth, G. Reinartz, H.T. Eich, B.M.P. Aleman, P. Barr & J. Yahalom. (2017) Early-stage mantle cell lymphoma: a retrospective analysis from the International Lymphoma Radiation Oncology Group (ILROG). Annals of Oncology 28:9, pages 2185-2190.
Crossref
Crossref
Michael Pfreundschuh. (2017) Age and Sex in Non-Hodgkin Lymphoma Therapy: It’s Not All Created Equal, or Is It?. American Society of Clinical Oncology Educational Book:37, pages 505-511.
Crossref
Crossref
Peng Yang, Jun Lin, Hao Liu, Hao Shen & Hui-Lin Yang. (2017) Primary bone mantle cell lymphomas with multiple vertebral compression fractures: A case report. Oncology Letters 13:3, pages 1288-1292.
Crossref
Crossref
Michael Schweizer & Evan Yu. (2017) AR-Signaling in Human Malignancies: Prostate Cancer and Beyond. Cancers 9:12, pages 7.
Crossref
Crossref
Stephen E. Spurgeon, Brian G. Till, Peter Martin, Andre H. Goy, Martin P. Dreyling, Ajay K. Gopal, Michael LeBlanc, John P. Leonard, Jonathan W. Friedberg, Lawrence Baizer, Richard F. Little, Brad S. Kahl & Mitchell R. Smith. (2016) Recommendations for Clinical Trial Development in Mantle Cell Lymphoma. Journal of the National Cancer Institute 109:1, pages djw263.
Crossref
Crossref
Sarah A. Milgrom. 2017. Radiation Therapy in Hematologic Malignancies. Radiation Therapy in Hematologic Malignancies
143
155
.
Matthieu Hanf, David Chiron, Sophie de Visme, Cyrille Touzeau, Herv? Maisonneuve, Henry Jardel, Catherine Pellat-Deceunynck, Martine Amiot & Steven le Gouill. (2016) The REFRACT-LYMA cohort study: a French observational prospective cohort study of patients with mantle cell lymphoma. BMC Cancer 16:1.
Crossref
Crossref
Marjolijn van Keep, Kerry Gairy, Divyagiri Seshagiri, Pushpike Thilakarathne & Dawn Lee. (2016) Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma. BMC Cancer 16:1.
Crossref
Crossref
Andre Goy. (2016) Mantle Cell Lymphoma. Hematology/Oncology Clinics of North America 30:6, pages 1345-1370.
Crossref
Crossref
Bryan Hambley, Paolo F. Caimi & Basem M. William. (2016) Bortezomib for the treatment of mantle cell lymphoma: an update. Therapeutic Advances in Hematology 7:4, pages 196-208.
Crossref
Crossref
Marco Ruella, Saad S. Kenderian, Olga Shestova, Joseph A. Fraietta, Sohail Qayyum, Qian Zhang, Marcela V. Maus, Xiaobin Liu, Selene Nunez-Cruz, Michael Klichinsky, Omkar U. Kawalekar, Michael Milone, Simon F. Lacey, Anthony Mato, Stephen J. Schuster, Michael Kalos, Carl H. June, Saar Gill & Mariusz A. Wasik. (2016) The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma. Clinical Cancer Research 22:11, pages 2684-2696.
Crossref
Crossref
Eva HosterAndreas RosenwaldFrançoise BergerHeinz-Wolfram BerndSylvia HartmannChristoph LoddenkemperThomas F.E. BarthNicole BrousseStefano PileriGrzegorz RymkiewiczRoman KodetStephan StilgenbauerRoswitha ForstpointnerCatherine ThieblemontMichael HallekBertrand CoiffierUrsula Vehling-KaiserRéda BouabdallahLothar KanzMichael PfreundschuhChristian SchmidtVincent RibragWolfgang HiddemannMichael UnterhaltJohanna C. Kluin-NelemansOlivier HermineMartin H. DreylingWolfram Klapper. (2016) Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network. Journal of Clinical Oncology 34:12, pages 1386-1394.
Crossref
Crossref
Dai Chihara, Chan Y. Cheah, Jason R. Westin, Luis E. Fayad, Maria A. Rodriguez, Fredrick B. Hagemeister, Barbara Pro, Peter McLaughlin, Anas Younes, Felipe Samaniego, Andre Goy, Fernando Cabanillas, Hagop Kantarjian, Larry W. Kwak, Michael L. Wang & Jorge E. Romaguera. (2016) Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center. British Journal of Haematology 172:1, pages 80-88.
Crossref
Crossref
Georg Hess, Bertrand Coiffier, Michael Crump, Christian Gisselbrecht, Fritz Offner, Jorge Romaguera, Lisa Kang & Pádraig J Moran. (2015) Effect of prognostic classification on temsirolimus efficacy and safety in patients with relapsed or refractory mantle cell lymphoma: a retrospective analysis. Experimental Hematology & Oncology 4:1.
Crossref
Crossref
Rohit Mathur, Lalit Sehgal, Frank K. Braun, Zuzana Berkova, Jorge Romaguerra, Michael Wang, M. Alma Rodriguez, Luis Fayad, Sattva S. Neelapu & Felipe Samaniego. (2015) Targeting Wnt pathway in mantle cell lymphoma-initiating cells. Journal of Hematology & Oncology 8:1.
Crossref
Crossref
Deborah M. Stephens & Stephen E. Spurgeon. (2015) Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion. Therapeutic Advances in Hematology 6:5, pages 242-252.
Crossref
Crossref
Irit Avivi & Andre Goy. (2015) Refining the Mantle Cell Lymphoma Paradigm: Impact of Novel Therapies on Current Practice. Clinical Cancer Research 21:17, pages 3853-3861.
Crossref
Crossref
R. Angelo de Claro, Karen M. McGinn, Nicole Verdun, Shwu-Luan Lee, Haw-Jyh Chiu, Haleh Saber, Margaret E. Brower, C.J. George Chang, Elimika Pfuma, Bahru Habtemariam, Julie Bullock, Yun Wang, Lei Nie, Xiao-Hong Chen, Donghao (Robert) Lu, Ali Al-Hakim, Robert C. Kane, Edvardas Kaminskas, Robert Justice, Ann T. Farrell & Richard Pazdur. (2015) FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia. Clinical Cancer Research 21:16, pages 3586-3590.
Crossref
Crossref
Yu Wang & Shuangge Ma. (2014) Racial differences in mantle cell lymphoma in the United States. BMC Cancer 14:1.
Crossref
Crossref
Waqar Haque, K. Ranh Voong, Ferial Shihadeh, Isidora Arzu, Chelsea Pinnix, Ali Mazloom, L. Jeffrey Medeiros, Jorge Romaguera, Alma Rodriguez, Michael Wang, Pamela Allen & Bouthaina Dabaja. (2014) Radiation Therapy Is an Effective Modality in the Treatment of Mantle Cell Lymphoma, Even in Heavily Pretreated Patients. Clinical Lymphoma Myeloma and Leukemia 14:6, pages 474-479.
Crossref
Crossref
Guru Subramanian Guru Murthy, Raji Venkitachalam & Paulette Mehta. (2014) Effect of Radiotherapy on the Survival of Patients With Stage I and Stage II Mantle Cell Lymphoma: Analysis of the Surveillance, Epidemiology and End Results Database. Clinical Lymphoma Myeloma and Leukemia 14, pages S90-S95.
Crossref
Crossref
Tiffany Tang & Peter Martin. (2014) Mantle Cell Lymphoma: Taking Therapeutic Advantage of New Insights into the Biology. Current Hematologic Malignancy Reports 9:3, pages 254-261.
Crossref
Crossref
Christophe Leux, Marc Maynadié, Xavier Troussard, Quentin Cabrera, Aurélie Herry, Sandra Le Guyader-Peyrou, Steven Le Gouill & Alain Monnereau. (2014) Mantle cell lymphoma epidemiology: a population-based study in France. Annals of Hematology 93:8, pages 1327-1333.
Crossref
Crossref
Tiffany Tang & Peter Martin. (2014) Role of ibrutinib for the treatment of mantle cell lymphoma in the elderly. International Journal of Hematologic Oncology 3:1, pages 53-61.
Crossref
Crossref
Zhi-Ming Li, Emanuele Zucca & Michele Ghielmini. (2013) Open questions in the management of mantle cell lymphoma. Cancer Treatment Reviews 39:6, pages 602-609.
Crossref
Crossref
Peter Kristian Rasmussen. (2013) Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: An investigation of clinical and histopathological features. Acta Ophthalmologica 91:thesis5, pages 1-27.
Crossref
Crossref
Antonino Carbone & Anas YounesKathrin Aprile von HohenstaufenAlden MocciaEmanuele Zucca. 2013. Non-Hodgkin Lymphomas: Advanced Diagnostics & Personalized Therapies. Non-Hodgkin Lymphomas: Advanced Diagnostics & Personalized Therapies
232
249
.
Alexander J. Ambinder, Pareen J. Shenoy, Loretta J. Nastoupil & Christopher R. Flowers. (2013) Using primary site as a predictor of survival in mantle cell lymphoma. Cancer 119:8, pages 1570-1577.
Crossref
Crossref
Ke-Jie Zhang & Michael Wang. (2013) Potential effects of CRM1 inhibition in mantle cell lymphoma. Chinese Journal of Cancer Research 24:4, pages 374-387.
Crossref
Crossref